Ocugen’s Clinical Calendar Packs a Punch in Q3 as Analysts Stay Bullish on Gene Therapy Pipeline

Ocugen's Q3 2026 milestones: rolling BLA for OCU400 and interim analysis for OCU410ST. Analysts bullish, $115M financing extends runway to 2028.

Ocugen is heading into a pivotal stretch, with two major pipeline milestones converging in the third quarter of 2026. The gene therapy developer plans to kick off a rolling Biologics License Application for its lead candidate OCU400 while simultaneously reading out an interim analysis from its phase 2/3 GARDian3 study of OCU410ST in Stargardt disease. The dual events have put the stock firmly on Wall Street’s radar, even as the shares languish near oversold levels.

Analyst sentiment has been building for weeks. In the span of seven days, four separate houses reiterated buy ratings on the stock. H.C. Wainwright, Chardan Capital and Oppenheimer all reaffirmed their bullish calls, while a fourth analyst held firm on a $12 price target as recently as May 11. Zacks Investment Research also upgraded Ocugen to a Rank 2 (“Buy”), citing a 23% upward trend in earnings estimates over recent months. The broader consensus is that Ocugen’s gene therapy platform — which targets rare retinal diseases with no approved therapies in either the US or Europe — offers a compelling risk-reward profile at current levels.

Those upgrades came on the heels of Ocugen’s first-quarter earnings report, which served up a mixed bag. The company posted a net loss of $0.06 per share, a penny wider than the $0.05 analysts had forecast. Revenue, however, surprised to the upside at $1.53 million, well above the consensus estimate of roughly $0.5 million. Operating expenses climbed to $19.4 million from $16.0 million a year earlier, with research and development accounting for $11.3 million and general and administrative costs totaling $8.1 million. The cash position at quarter-end stood at $32.2 million, more than double the year-ago number but still insufficient to cover the growing burn rate.

Ocugen moved quickly to address that. Early this month, the company completed a $115 million private placement of convertible notes bearing a 6.75% coupon and maturing in 2034. After repaying existing Avenue debt and accounting for fees, Ocugen expects to hold around $112 million in cash, equivalents and restricted funds — enough to keep the lights on through 2028. If Janus Henderson, the note’s lead investor, exercises additional warrants, an extra $15 million could flow in, pushing the estimated stash to $127 million.

That financial runway is meant to carry the pipeline into a series of regulatory submissions. The most immediate catalyst is the rolling BLA for OCU400, a one-time gene therapy for retinitis pigmentosa that is designed to work independently of the causative mutation. The rolling submission is slated to start in the third quarter of 2026 and wrap up by the second quarter of 2027. For OCU410ST, the Stargardt disease candidate, the GARDian3 trial has already enrolled all 63 patients — ahead of schedule — and the interim analysis will be triggered when 24 patients complete eight months of follow-up. That readout is expected in Q3 2026, with topline data following in Q2 2027. A third BLA filing for OCU410, a different gene therapy program, is targeted by 2028.

The interim analysis has a clear benchmark. In the phase 1 GARDian1 study, treated eyes showed a 54% slower expansion of atrophic retinal lesions over 12 months compared with untreated fellow eyes, with no serious adverse events. Investors will be watching closely to see whether the phase 2/3 data can replicate that magnitude of effect.

Despite the analyst support and the pipeline momentum, the stock has struggled. Shares currently trade around $1.26, roughly 42% below their March high and down about 19% over the past month. The relative strength index hovers near 30, signalling oversold territory. Whether the summer catalysts can reverse the slide depends entirely on how well the GARDian3 interim results stack up against the phase 1 proof-of-concept data — and on the market’s willingness to look past near-term dilution risks.